Scientific rationale for a higher dose of nusinersen.
Richard S FinkelMonique M RyanSamuel Ignacio Pascual PascualJohn W DayEugenio MercuriDarryl C De VivoRichard FosterJacqueline MontesJuliana Gurgel-GiannettiDrew MacCannellZdenek BergerPublished in: Annals of clinical and translational neurology (2022)
Our data indicate that a higher dose of nusinersen may lead to additional clinically meaningful improvement in efficacy when compared with the currently approved 12-mg dose. The efficacy, safety, and PK of a higher nusinersen dose are currently under investigation in the ongoing phase 2/3 DEVOTE study (NCT04089566).